GlassScriptPhysician profile
Kristen Allcorn Killen
NPI 1144679960
$3,753.61
in general payments reported to CMS, 2019-2025
31 companies · $422 in 2025
The $422 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $440 · 2020: $624 · 2021: $1,763 · 2022: $505 · 2023: $0.79 · 2025: $422.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $422 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $421.99 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $756.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $482.42 | 2019-2022 | |
| Lilly USA, LLC | $404.61 | 2019-2025 | Zepbound |
| Astrazeneca Pharmaceuticals LP | $393.16 | 2019-2025 | Breztri, Farxiga |
| Novo Nordisk INC | $335.70 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $299.66 | 2020-2022 | |
| Abbvie INC. | $155.88 | 2021-2025 | |
| Glaxosmithkline, LLC. | $146.46 | 2019-2025 | Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $136.74 | 2021-2022 | |
| Grifols USA, LLC | $97.59 | 2019 | |
| Amgen INC. | $91.28 | 2019-2022 | |
| Abbott Laboratories | $53.59 | 2022-2025 | Freestyle Libre |
| E.R. Squibb & Sons, L.L.C. | $52.29 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.90 | 2019-2020 | |
| Jazz Pharmaceuticals INC. | $43.71 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $32.17 | 2020 | |
| Inspire Medical Systems, INC. | $29.41 | 2025 | Inspire |
| Biohaven Pharmaceutical Holding Company LTD. | $25.31 | 2022 | |
| Astellas Pharma US INC | $23.02 | 2025 | Veozah |
| Antares Pharma, INC. | $16.16 | 2025 | Xyosted |
| Exact Sciences Corporation | $15.36 | 2025 | Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $14.27 | 2019 | |
| Amarin Pharma, INC. | $13.28 | 2020 | |
| Merck Sharp & Dohme LLC | $12.61 | 2019 | |
| Eisai INC. | $12.25 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.22 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.71 | 2021 | |
| Allergan, INC. | $11.48 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $11.29 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.04 | 2021 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kristen Killen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.